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Association between quadrivalent human  papillomavirus 
 vaccination and selected syndromes with autonomic  
dysfunction in Danish females: population based,  
self-controlled, case series analysis
Anders Hviid,1,5 Nicklas M Thorsen,1 Palle Valentiner-Branth,2 Morten Frisch,1,3 Kåre Mølbak2,4
ABSTRACT
OBJECTIVE
To evaluate the association between quadrivalent 
human papillomavirus vaccination and syndromes 
with autonomic dysfunction, such as chronic fatigue 
syndrome, complex regional pain syndrome, and 
postural orthostatic tachycardia syndrome.
DESIGN
Population-based self-controlled case series.
SETTING
Information on human papillomavirus vaccinations 
and selected syndromes with autonomic 
dysfunction (chronic fatigue syndrome, complex 
regional pain syndrome, and postural orthostatic 
tachycardia syndrome) identified using ICD-10 
(international classification of diseases, revision 
10) diagnostic codes from Danish nationwide 
registers.
PARTICIPANTS
869 patients with autonomic dysfunction syndromes 
from a cohort of 1 375 737 Danish born female 
participants aged 10 to 44 years during 2007-16.
MAIN OUTCOME MEASURES
Self-controlled case series rate ratios (95% 
confidence intervals) of the composite outcome of 
chronic fatigue syndrome, complex regional pain 
syndrome, and postural orthostatic tachycardia 
syndrome, adjusted for age and season, comparing 
female participants vaccinated and unvaccinated 
with the quadrivalent human papillomavirus vaccine. 
Chronic fatigue syndrome, complex regional pain 
syndrome, and postural orthostatic tachycardia 
syndrome were also considered separately in 
secondary analyses.
RESULTS
During 10 581 902 person years of follow-up, 869 
female participants with syndromes of autonomic 
dysfunction (136 with chronic fatigue syndrome, 
535 with complex regional pain syndrome, and 198 
with postural orthostatic tachycardia syndrome) 
were identified. Quadrivalent human papillomavirus 
vaccination did not statistically significantly increase 
the rate of a composite outcome of all syndromes 
with autonomic dysfunction in a 365 day risk 
period following vaccination (rate ratio 0.99, 95% 
confidence interval 0.74 to 1.32) or the rate of any 
individual syndrome in the risk period (chronic fatigue 
syndrome (0.38, 0.13 to 1.09), complex regional pain 
syndrome (1.31, 0.91 to 1.90), or postural orthostatic 
tachycardia syndrome (0.86, 0.48 to 1.54)).
CONCLUSIONS
When vaccination is introduced, adverse events 
could occur in close temporal relation to the vaccine 
purely by chance. These results do not support a 
causal association between quadrivalent human 
papillomavirus vaccination and chronic fatigue 
syndrome, complex regional pain syndrome, or 
postural orthostatic tachycardia syndrome, either 
individually or as a composite outcome. An increased 
risk of up to 32% cannot be formally excluded, but the 
statistical power of the study suggests that a larger 
increase in the rate of any syndrome associated with 
vaccination is unlikely.
Introduction
Human papillomavirus vaccines have been used in 
national immunisation programmes worldwide for 
more than a decade, with great success.1 In countries 
such as Denmark, Japan, and Ireland, however, 
national immunisation programmes have had serious 
setbacks owing to concerns about safety.2 3 These 
concerns have originated from anecdotal links between 
human papillomavirus vaccines and syndromes 
with autonomic dysfunction, such as chronic fatigue 
syndrome, postural orthostatic tachycardia syndrome, 
and complex regional pain syndrome.4-6 Rapid spread 
on social media and sensationalist media coverage 
have fuelled these concerns. 
Chronic fatigue syndrome, postural orthostatic 
tachycardia syndrome, and complex regional pain 
syndrome are complex disorders characterised by 
autonomic dysfunction, and present with many 
unspecific symptoms, such as headache, dizziness, 
and nausea.7-9 Consequently, these syndromes, 
especially chronic fatigue syndrome and postural 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Anecdotal links between human papillomavirus vaccination and syndromes with 
autonomic dysfunction, such as chronic fatigue syndrome, complex regional pain 
syndrome, and postural orthostatic tachycardia syndrome, have been reported
Concerns about human papillomavirus vaccine persist and challenge cancer 
prevention in several countries through disappointing uptake of the vaccine
WHAT THIS STUDY ADDS
Our study did not support the hypothesis that quadrivalent human 
papillomavirus vaccine increases the risk of selected syndromes with autonomic 
dysfunction (chronic fatigue syndrome, complex regional pain syndrome, and 
postural orthostatic tachycardia syndrome) in Danish girls and women
A moderate to large increase in the rate (more than 32%) of any syndrome 
associated with vaccination is unlikely given the statistical power of our study
copyright.
 o
n
 14 Septem
ber 2020 at Kobenhavns Universitets Bibliotek. Protected by
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m2930 on 2 September 2020. Downloaded from 
RESEARCH
2 doi: 10.1136/bmj.m2930 | BMJ 2020;370:m2930 | the bmj
orthostatic tachycardia syndrome, could individually 
have a wide range of unique presentations, and also 
considerable clinical overlap.5 10
In 2015, the European Medicines Agency 
concluded that there was no evidence that the human 
papillomavirus vaccine caused postural orthostatic 
tachycardia syndrome and complex regional pain 
syndrome.11 This conclusion was echoed in a 2019 
statement from the American Autonomic Society.12 
Most observational studies on the association of 
human papillomavirus vaccines and syndromes 
with autonomic dysfunction have evaluated chronic 
fatigue syndrome, including studies from the United 
Kingdom, Norway, Finland, and the Netherlands, 
which all reported no such association.13-16 The 
Finnish study also evaluated postural orthostatic 
tachycardia syndrome and complex regional pain 
syndrome. This study’s results again suggested no 
increased risk associated with human papillomavirus 
vaccination.15 The clinical overlap between 
syndromes does support extrapolation and provides 
reassurance of the safety of human papillomavirus 
vaccines for autonomic dysfunctions. More evidence is 
needed, however, and examination of the association 
between human papillomavirus vaccination and 
complex regional pain syndrome and postural 
orthostatic tachycardia syndrome specifically, would 
be valuable. Furthermore, only the Norwegian study 
evaluated the quadrivalent human papillomavirus 
vaccine, whereas the three other studies evaluated 
the bivalent vaccine. 
We took advantage of the unique Danish nationwide 
registers and evaluated the association between the 
quadrivalent human papillomavirus vaccine and 
chronic fatigue syndrome, complex regional pain 
syndrome, and postural orthostatic tachycardia 
syndrome in a self-controlled case series analysis 
nested in a nationwide cohort of Danish female 
participants aged 10-44 years in 2007-16.
Methods
Study cohort
Denmark has a longstanding tradition of nationwide 
population based registers facilitating high quality 
epidemiological research. The key administrative 
and demographic register in Denmark is the Civil 
Registration System.17 This register contains 
information on date of birth and familial links, 
together with daily updated information on vital 
status, civil status, and place of residence for every 
person residing in Denmark. This information is 
indexed by a unique identifier, which is used in all 
national registers and permits the construction of large 
nationwide cohorts with individual level information 
from many different sources. We constructed a study 
cohort of all Danish-born female participants aged 
10-44 years in the period 2007-16 with information 
on human papillomavirus vaccination status and 
possible diagnoses of chronic fatigue syndrome, 
postural orthostatic tachycardia syndrome, and 
complex regional pain syndrome. The study was 
approved by the Danish Data Protection Agency 
(approval No 2015-57-0102). Ethical approval is not 
required for register based research in Denmark.
Vaccination
We obtained information on dates of human 
papillomavirus vaccination in the study cohort from 
the Danish vaccination register.18 The quadrivalent 
human papillomavirus vaccine (Gardasil, Merck Sharp 
and Dohme) was licensed in Europe in September 
2006. In Denmark, universal vaccination of girls 
aged 12 with the quadrivalent human papillomavirus 
vaccine was started in January 2009, with catch-up 
vaccination of girls aged 13-15 starting in October 
2008. Vaccination of women aged 20-27 was started 
in August 2012. Three doses of the vaccine in total 
were originally given, with the second and third doses 
administered two and six months, respectively, after 
the first dose. A schedule requiring two doses was 
introduced in August 2014 for girls given the first 
dose at age 12-13. The bivalent vaccine (Cervarix, 
GlaxoSmithKline) replaced the quadrivalent vaccine in 
February 2016. 
The Danish vaccination register comprises human 
papillomavirus vaccinations administered as part of 
the free national childhood vaccination programme 
and also vaccinations privately purchased and given to 
those not eligible for the national programme.
Selected syndromes with autonomic dysfunction
Denmark healthcare is financed by tax payers, and 
general practitioners act as gatekeepers for referrals 
to specialists.19 Our information on syndromes 
with autonomic dysfunction, in the form of chronic 
fatigue syndrome, complex regional pain syndrome, 
and postural orthostatic tachycardia syndrome, was 
obtained from the Danish National Patient Register.20 
This register comprises information on all hospital 
patients in Denmark, including dates of admission 
and discharge, the care setting (that is, inpatient, 
outpatient, and emergency department services), 
diagnoses, procedures, and operations. Diagnoses 
are coded using ICD-10 (international classification of 
diseases, 10th revision). 
As primary outcomes in the study, we included 
those with the following ICD-10 codes: postviral 
fatigue syndrome G93.3 and G93.3A for chronic 
fatigue syndrome; algoneurodystrophy M89.0 for 
complex regional pain syndrome (the recommended 
code for complex regional pain syndrome according to 
Danish guidelines); and supraventricular tachycardia, 
postural orthostatic tachycardia syndrome I47.1J 
for postural orthostatic tachycardia syndrome (this 
code is a Danish ICD-10 modification not present 
in the standard ICD-10). As a secondary outcome 
we included F45 and F48.0 (somatoform disorders 
and neurasthenia). We included both inpatients and 
outpatients and patients at emergency departments. 
Only the first outcome diagnosis was included, 
and thus, individuals are included only once in our 
analyses.
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Statistical analysis
We followed up individual female participants in the 
study cohort from age 10 or 1 January 2007, whichever 
event came later, until the 45th birthday, 1 January 
2017, emigration, death, or disappearance from the 
Civil Registration System, whichever event came first. 
Human papillomavirus vaccination was considered to 
be a time dependent variable with the possibility that 
both unvaccinated and vaccinated individuals could 
contribute to follow-up. Female participants who 
received human papillomavirus vaccines other than 
the quadrivalent human papillomavirus vaccine were 
censored. Chronic fatigue syndrome, complex regional 
pain syndrome, and postural orthostatic tachycardia 
syndrome were analysed as a composite outcome in the 
main analysis, but each was also considered separately 
in secondary analyses.
The number of cases and person time of follow-up 
were aggregated according to vaccination status, age, 
and calendar period, and used to calculate incidence 
rates. In this descriptive analysis, any primary study 
outcome diagnosis was a censoring event.
We used the self-controlled case series method 
to compare the incidence rate of syndromes in a 
predefined risk period after vaccination with the 
quadrivalent human papillomavirus vaccine and the 
incidence rate in all other periods of follow-up for 
individual female participants with a study outcome.21 
In the self-controlled case series analysis, follow-up 
was not censored at diagnosis of any syndrome, and 
individuals contributed to the risk period of interest 
every time they received a dose of the vaccine. The “self-
controlling” aspect of this approach provides implicit 
adjustment for all time independent covariates. 
Three key assumptions must be fulfilled for the self-
controlled case series to provide valid estimates.22 
Firstly, study outcomes must be either recurrent and 
independent or unique. Secondly, outcomes must not 
be fatal. Thirdly, experiencing an outcome must not 
influence future risk of exposure. Rate ratios (with 
95% confidence intervals) comparing incidence rates 
according to vaccination status were estimated using 
conditional Poisson regression (conditional on the 
individual female participants). Unless otherwise 
specified, we adjusted rate ratios for age (ages 10-35 in 
one year intervals, 36-41 in two year intervals, 42-44 
years of age) and season (January-March, April-June, 
July-September, October-December). We predefined a 
risk period of 365 days after the last vaccination for 
our main analysis to allow for a possible insidious 
onset and delayed clinical investigation owing to the 
complex nature of the study outcomes. The risk period 
was re-entered for each additional dose of vaccine 
received. Thus an individual receiving three doses of 
vaccine with two and four month intervals between 
the doses, contributed 18 months (2+4+12 months) of 
follow-up to the one year risk period (supplementary 
fig S1). 
In sensitivity analyses, we explored alternative risk 
periods (0-91 days, 92-181 days, 182-365 days, 366 
or more days after the last vaccination), excluded the 
periods immediately before and after vaccination (seven 
days before and seven days after last vaccination), 
compared the main risk period (0-365 days after 
the last vaccination) only with the later vaccinated 
period (more than 365 days after the last vaccination), 
and conducted stratified analyses of the main risk 
period effect in strata according to age and calendar 
period. We also evaluated the association between 
quadrivalent human papillomavirus vaccination and a 
secondary study outcome (somatoform disorders and 
neurasthenia). Finally, we also estimated the rate ratio 
for any syndrome comparing the 365 day risk period 
with referent period rates in the full cohort using 
Poisson regression, with adjustment for age, calendar 
period, and season.
Previous studies have shown a link between 
healthcare use and later diagnosis of chronic fatigue 
syndrome or reporting of serious adverse events after 
human papillomavirus vaccination.14 23 We estimated 
the risk of being diagnosed with an autonomic 
dysfunction syndrome conditional on healthcare use 
at baseline and evaluated the association between 
quadrivalent human papillomavirus vaccination and 
any syndrome in the resulting risk strata (details of 
methods and results are given in the supplementary 
material).
Data management and statistical analyses were 
conducted using R version 3.5.1 (R Core Team, 2017). 
Analyses were conducted using the SCCS package. For 
data manipulation and plots we used the packages 
eeptools, data.table, plyr, ggsci, ggplot2, and gridExtra. 
All packages available from https://cran.r-project.org/
web/packages/.
Patient and public involvement
Our study was conducted in response to public 
concerns about vaccine safety. The inclusion of specific 
outcomes in our study was informed by public and 
patient anecdotal information.
Results
Our study cohort included 1 375 737 Danish-born 
female participants aged 10-44 years during the 
2007-16 study period. During 10 581 092 person 
years of follow-up, 23 493 study participants were 
lost to follow-up (19 273 due to emigration, 4069 
to death, 151 to disappearance) and 11 931 were 
censored owing to vaccination with other human 
papillomavirus vaccines. In the study cohort, 529 547 
female participants received at least one dose of the 
quadrivalent human papillomavirus vaccine. Among 
girls aged 10-17, vaccines were given at a median age 
of 12.6 years (interquartile range 2.0), and among 
women aged 18-44 at a median age of 24.3 years 
(4.9). We observed chronic fatigue syndrome, complex 
regional pain syndrome, and postural orthostatic 
tachycardia syndrome in 869 participants of the study 
cohort, corresponding to an incidence rate of 8.21 
per 100 000 person years. Complex regional pain 
syndrome was the most common syndrome, occurring 
in 535 participants, followed by postural orthostatic 
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tachycardia syndrome in 198 and chronic fatigue 
syndrome in 136. 
The incidence rates for all syndromes increased 
throughout the study period, being especially marked 
for postural orthostatic tachycardia syndrome and also 
reflected in the composite outcome of any syndrome 
(table 1). For all syndromes, the incidence rates were 
highest among adolescent girls. The incidence rates 
for postural orthostatic tachycardia syndrome declined 
markedly with increasing age, whereas those for chronic 
fatigue syndrome and complex regional pain syndrome 
showed a U shape with slight increases in older women 
(table 1). The median age at diagnosis of any syndrome 
was 14.0 years (interquartile range 3.6) among girls 
aged 10-17, and 33.3 years (13.5) among women aged 
18-44 (table 2). Among individuals with any syndrome, 
the median age at first vaccination was 12.3 years 
(interquartile range 0.8) among girls aged 10-17, and 
21.9 years (9.8) among women aged 18-44 (table 2). 
Among 433 individuals with a syndrome diagnosis 
vaccinated during the study period (55 with chronic 
fatigue syndrome, 223 with complex regional 
pain syndrome, and 155 with postural orthostatic 
tachycardia syndrome), most received a diagnosis after 
vaccination; this diagnosis was especially marked for 
chronic fatigue syndrome and postural orthostatic 
tachycardia syndrome (fig 1A) and particularly 
pronounced in the later study period (fig 1B).
In the self-controlled case series analysis, chronic 
fatigue syndrome occurred in four individuals, complex 
regional pain syndrome in 49, and postural orthostatic 
tachycardia syndrome in 19 within the one year risk 
period after vaccination. Follow-up in the one year 
risk period was primarily composed of contributions 
from adolescent girls vaccinated according to schedule 
(supplementary fig S2). No statistically significantly 
increased rate was found between quadrivalent 
human papillomavirus vaccination and any syndrome 
(rate ratio 0.99, 95% confidence interval 0.74 to 
1.32), chronic fatigue syndrome (0.38, 0.13 to 1.09), 
complex regional pain syndrome (1.31, 0.91 to 1.90), 
or postural orthostatic tachycardia syndrome (0.86, 
0.48 to 1.54) (table 3). We conducted a number 
of sensitivity analyses of the association between 
quadrivalent human papillomavirus vaccination 
and any syndrome (table 4). No association was 
found between quadrivalent human papillomavirus 
vaccination and any syndrome in girls aged 10-17 
(rate ratio 0.81, 95% confidence interval 0.56 to 1.18) 
or in women aged 18-44 (1.36, 0.87 to 2.12), in the 
period before 1 January 2015 (1.00, 0.73 to 1.36) or 
after (0.80, 0.37 to 1.71) (table 4).
Removing the seven day period just before and 
after vaccination or removing unvaccinated follow-
up from the reference period had little effect (rate 
ratio 1.02, 95% confidence interval 0.76 to 1.37 and 
0.96, 0.68 to 1.35, respectively, table 4). When a 
number of additional risk periods were examined no 
increased rates were found (0-91 days: rate ratio 0.81; 
92-181 days: 1.00; 182-365 days: 1.32; all estimates 
statistically non-significant; table 4). We analysed 
a secondary outcome (somatoform disorders and 
neurasthenia) and found no increased rate in the one 
year risk period after vaccination (rate ratio 0.95, 95% 
confidence interval 0.79 to 1.14). Comparison of the 
365 day risk period and referent period rates in the full 
cohort using Poisson regression, with adjustment for 
age, calendar period, and season, yielded a rate ratio 
for any syndrome of 0.90 (95% confidence interval 
0.67 to 1.18).
Discussion
Principal findings
In a self-controlled case series analysis of 869 cases 
nested in a large nationwide cohort comprising 1.4 
million Danish female participants, we observed 
no association between quadrivalent human 
papillomavirus vaccination and the rates of chronic 
fatigue syndrome, postural orthostatic tachycardia 
syndrome, or complex regional pain syndrome.
Comparison with other studies
The pathophysiology of chronic fatigue syndrome, 
postural orthostatic tachycardia syndrome, 
and complex regional pain syndrome is poorly 
understood.24 25 Human papillomavirus vaccination 
Table 1 | Incidence rates (95% confidence intervals) per 100 000 years of follow-up of selected syndromes with autonomic dysfunction among 
1 375 737 female participants aged 10-44 years, born in Denmark between 2007 and 2016
Characteristics
No of person 
years of 
follow-up 
(100 000 years)
Any syndrome Chronic fatigue syndrome
Complex regional pain 
syndrome
Postural orthostatic 
 tachycardia syndrome
No of 
cases
IR (95% CI)  
(per 100 000 years)
No of 
cases
IR (95% CI)  
(per 100 000 years)
No of 
cases
IR (95% CI) (per 
100 000 years)
No of 
cases
IR (95% CI) 
(per 100 000 years)
Overall 105.81 869 8.21 (7.68 to 8.77) 136 1.29 (1.08 to 1.51) 535 5.06 (4.64 to 5.50) 198 1.87 (1.62 to 2.14)
Period:
 2007-08 21.80 100 4.59 (3.75 to 5.55) 22 1.01 (0.64 to 1.49) 77 3.53 (2.80 to 4.38) 1 0.05 (0.003 to 0.20)
 2009-10 21.49 102 4.75 (3.88 to 5.73) 16 0.74 (0.44 to 1.17) 80 3.72 (2.97 to 4.60) 6 0.28 (0.11 to 0.57)
 2011-12 21.16 163 7.70 (6.58 to 8.95) 23 1.09 (0.70 to 1.59) 112 5.29 (4.37 to 6.34) 28 1.32 (0.89 to 1.88)
 2013-14 20.86 240 11.51 (10.11 to 13.03) 39 1.87 (1.34 to 2.52) 131 6.28 (5.27 to 7.42) 70 3.36 (2.63 to 4.21)
 2015-16 20.51 264 12.87 (11.38 to 14.49) 36 1.76 (1.24 to 2.39) 135 6.58 (5.53 to 7.76) 93 4.53 (3.67 to 5.52)
Age (years):
 10-17 25.21 323 12.81 (11.47 to 14.26) 43 1.71 (1.25 to 2.27) 167 6.62 (5.67 to 7.68) 113 4.48 (3.71 to 5.36)
 18-24 20.70 128 6.18 (5.17 to 7.32) 15 0.72 (0.42 to 1.16) 68 3.29 (2.56 to 4.13) 45 2.17 (1.60 to 2.87)
 25-34 26.83 175 6.52 (5.60 to 7.54) 31 1.16 (0.79 to 1.61) 115 4.29 (3.55 to 5.12) 29 1.08 (0.73 to 1.52)
 35-44 33.07 243 7.35 (6.46 to 8.31) 47 1.42 (1.05 to 1.87) 185 5.59 (4.83 to 6.44) 11 0.33 (0.17 to 0.57)
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has been proposed to increase the risk of syndromes 
with autonomic dysfunction through autoimmune 
mechanisms.26 Autoantibodies have been described 
in patients with chronic fatigue syndrome, postural 
orthostatic tachycardia syndrome, and complex 
regional pain syndrome, and viral infections 
precipitating the onset of chronic fatigue syndrome 
have been reported.27-30 Complex regional pain 
syndrome has been seen after vaccination with other 
vaccines, such as hepatitis B vaccine and rubella 
vaccine in adolescent girls, possibly provoked by 
needle trauma.31 32
Table 2 | Descriptive characteristics of 869 cases of autonomic dysfunction syndrome among female participants aged 
10-44 born in Denmark during 2007-16. Results are shown as median (interquartile range)
Characteristics Any syndrome
Chronic fatigue 
syndrome
Complex regional 
pain syndrome
Postural orthostatic 
tachycardia syndrome
Age at study entry (years):
 All patients with a syndrome diagnosis 17.76 (19.72) 21.05 (19.18) 23.14 (22.34) 10.00 (6.27)
 Girls aged 10-17 10.00 (0.00) 10.00 (2.01) 10.00 (0.00) 10.00 (0.00)
 Women aged 18-44 27.59 (14.07) 27.93 (12.88) 29.06 (12.37) 17.18 (9.57)
Age at first vaccination (years)*:
 All patients with a syndrome diagnosis 13.04 (8.39) 15.48 (9.35) 13.28 (9.46) 12.52 (2.47)
 Girls aged 10-17 12.25 (0.76) 13.04 (2.73) 12.23 (0.75) 12.21 (0.46)
 Women aged 18-44 21.91 (9.79) 22.33 (6.89) 23.37 (6.25) 16.76 (8.91)
Age at diagnosis (years):
 All patients with a syndrome diagnosis 24.11 (21.08) 28.44 (20.74) 29.26 (22.71) 16.87 (8.52)
 Girls aged 10-17 13.99 (3.55) 14.66 (4.03) 13.20 (3.10) 14.60 (2.99)
 Women aged 18-44 33.31 (13.54) 35.00 (11.84) 35.07 (11.79) 24.46 (8.44)
Time from first vaccination to diagnosis (years)*:
 All patients with a syndrome diagnosis 1.86 (3.89) 2.17 (5.08) 1.05 (3.63) 2.95 (3.22)
 Girls aged 10-17 1.52 (3.51) 1.92 (4.30) 0.73 (3.33) 2.15 (2.25)
 Women aged 18-44 2.53 (5.47) 2.63 (7.09) 1.62 (4.34) 4.63 (3.62)
*Among vaccinated patients with a syndrome diagnosis (n=433).
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Autonomic dysfunction syndrome
Year of diagnosis
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Fig 1 | Frequency of autonomic dysfunction syndrome (chronic fatigue syndrome, postural orthostatic tachycardia 
syndrome, and complex regional pain syndrome) (A) before and after vaccination and (B) according to year of 
diagnosis before and after vaccination among Danish female participants aged 10-44 years during 2007-16 (only 
vaccinated patients with a syndrome diagnosis, n=433)
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Several observational studies have evaluated 
the association between human papillomavirus 
vaccination and syndromes with autonomic 
dysfunction. Donegan and colleagues conducted a 
self-controlled case series analysis of 187 girls with 
fatigue syndrome (chronic fatigue syndrome/myalgic 
encephalomyelitis, postviral fatigue syndrome, 
fibromyalgia, neurasthenia) from the UK Clinical 
Practice Research Datalink.13 No association was 
found in the year after vaccination with the first dose of 
the bivalent human papillomavirus vaccine (rate ratio 
1.07, 95% confidence interval 0.57 to 2.00). 
Feiring and colleagues conducted a survival analysis 
of 176 453 girls from the Norwegian Patient Registry, 
including 407 girls with chronic fatigue syndrome/
myalgic encephalomyelitis.14 No association with 
the quadrivalent human papillomavirus vaccine was 
found (hazard ratio 0.86, 95% confidence interval 
0.69 to 1.08). Norwegian guidelines recommend that 
chronic fatigue syndrome/myalgic encephalomyelitis 
in childhood and adolescence should be diagnosed 
by a paediatrician in a specialised healthcare setting; 
73% of adolescents diagnosed as having chronic 
fatigue syndrome/myalgic encephalomyelitis in 
Norway fulfilled the Fukuda criteria in another study.33 
Furthermore, the authors argue that in Norway, patients 
with postural orthostatic tachycardia syndrome 
are likely to be diagnosed as having chronic fatigue 
syndrome/myalgic encephalomyelitis. It is noteworthy 
that the incidence of chronic fatigue syndrome/myalgic 
encephalomyelitis is about 10-fold higher in Norway 
than in Denmark. This disparity is unlikely to represent 
a real difference but is more likely to represent different 
diagnostic practices and traditions. In Norway, an 
increase in the incidence of chronic fatigue syndrome/
myalgic encephalomyelitis was seen during 2009 
to 2014, which was independent of the human 
papillomavirus vaccine and was seen in both sexes. 
In a small Dutch self-controlled case series of 16 
vaccinated girls with longlasting fatigue from primary 
care, no association was found with the bivalent 
human papillomavirus vaccine (rate ratio 0.62, 95% 
confidence interval 0.07 to 5.49) in the year after any 
dose.16
In a Finnish cohort of 240 605 girls, Skufca and 
colleagues evaluated the association between bivalent 
human papillomavirus vaccine and 38 outcomes 
identified using the Finnish national hospital discharge 
register, including chronic fatigue syndrome (n=355), 
complex regional pain syndrome (n=14), and postural 
orthostatic tachycardia syndrome (n=37).15 No increased 
risk was found to be associated with the vaccine: chronic 
fatigue syndrome, hazard ratio 0.75 (95% confidence 
interval 0.59 to 0.95); complex regional pain syndrome, 
0.34 (0.11 to 1.05); and postural orthostatic tachycardia 
syndrome, 0.99 (0.46 to 2.11). 
These observational studies used analytical 
longitudinal study designs and provide reassuring 
results from different countries and different settings 
of care (from both general practice and hospitals). 
Only one of four studies, however, evaluated the 
quadrivalent human papillomavirus vaccine. Most 
studied patients with chronic fatigue syndrome or 
fatigue related illness, and the studies focused on 
adolescent girls. We provide reassuring support for 
the safety of the quadrivalent human papillomavirus 
vaccine also in adult female populations with catch-
up vaccination and vaccinations outside the national 
programme by individual choice. A considerable 
proportion of reports of serious adverse events after 
human papillomavirus vaccination have been reported 
by women.34 Our study is also by far the largest of 
the associations between human papillomavirus 
vaccination and complex regional pain syndrome and 
postural orthostatic tachycardia syndrome diagnoses.
Strength and limitations of this study
Our study had a number of limitations. Outcomes 
defined by diagnostic codes are widely used for 
Table 3 | Self-controlled case series analysis of quadrivalent human papillomavirus 
vaccination and rate of selected syndromes with autonomic dysfunction in Danish 
female participants
Risk period
No of 
cases
No of  person 
years
Crude rate ratio 
(95% CI)
Adjusted rate ratio 
(95% CI)*
Any syndrome:
 Reference period† 797 6735 1 (reference) 1 (reference)
 0-365 days after vaccination 72 644 0.87 (0.68 to 1.13) 0.99 (0.74 to 1.32)
Chronic fatigue syndrome:
 Reference period† 132 1100 1 (reference) 1 (reference)
 0-365 days after vaccination 4 79 0.41 (0.15 to 1.15) 0.38 (0.13 to 1.09)
Complex regional pain syndrome:
 Reference period† 486 4242 1 (reference) 1 (reference)
 0-365 days after vaccination 49 339 1.21 (0.88 to 1.67) 1.31 (0.91 to 1.90)
Postural orthostatic tachycardia syndrome:
 Reference period† 179 1393 1 (reference) 1 (reference)
 0-365 days after vaccination 19 226 0.59 (0.37 to 0.96) 0.86 (0.48 to 1.54)
*Adjusted for age in one year categories (except in the older part of the cohort where the groupings 36-37, 38-
39, 40-41, and 42-44 are used) and season (January-March, April-June, July-September, October-December).
†Comprising unvaccinated follow-up and follow-up from the period 366 days or more after vaccination.
Table 4 | Sensitivity analyses of the association between human papillomavirus 
vaccination and rate of any syndrome
Adjusted rate ratio  
(95% CI)‡
No of cases 
in risk period
No of person 
years
Main analysis of any syndrome* 0.99 (0.74 to 1.32) 72 644
Stratified analyses of the 0-365 days after vaccination v referent period rate ratio
Risk periods for different age groups:
 Girls aged 10-17 0.81 (0.56 to 1.18) 47 458
 Women aged 18-44 1.36 (0.87 to 2.12) 25 187
Risk periods before and after 1 January 2015:
 Before 1 January 2015 1.00 (0.73 to 1.36) 63 593
 From 1 January 2015 0.80 (0.37 to 1.71) 9 51
Alternative risk periods and referent periods
Time after vaccination v referent period (days)†:
 0-91 0.81 (0.48 to 1.34) 21 263
 92-181 1.00 (0.56 to 1.76) 16 153
 182-365 1.32 (0.83 to 2.10) 35 228
 ≥366 days 1.12 (0.75 to 1.68) 237 1667
Excluding 7 days before and after vaccination 
from the main analysis 1.02 (0.76 to 1.37) 71 606
0-365 days after vaccination risk period v ≥366 
days after vaccination 0.96 (0.68 to 1.35) 72 644
*Any syndrome adjusted rate ratio comparing 0-365 days after vaccination with the referent period (table 3).
†Referent period comprising only unvaccinated follow-up.
‡Adjusted for age in one year categories (except in the older part of the cohort where the groupings 36-37, 38-39,
40-41, and 42-44 are used) and season (January-March, April-June, July-September, October-December).
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epidemiological research in the Danish National 
Patient Registry,35 but the diagnostic validity of 
the ICD-10 codes used in our study has not been 
established in Denmark. Diagnosis of these conditions 
is complex, and the possibility of misclassification and 
under-ascertainment cannot be discounted. In view 
of the wide publicity about the safety of vaccination, 
girls vaccinated with the human papillomavirus 
vaccine might be more likely to be diagnosed as having 
syndromes with autonomic dysfunction, resulting in 
a falsely increased rate ratio, especially in the later 
periods of the study. More patients have diagnoses 
after vaccination in our study (fig 1), especially in 
the later periods. This is not reflected in the adjusted 
self-controlled case series analyses, including in 
the stratification by calendar period (table 4). Any 
misclassification of patients as having chronic fatigue 
syndrome, complex regional pain syndrome, and 
postural orthostatic tachycardia syndrome could 
bias the observed associations. Patients most likely 
to be misclassified are those with at least some of 
the symptoms specific for chronic fatigue syndrome, 
complex regional pain syndrome, and postural 
orthostatic tachycardia syndrome, which may also 
be valuable to include in a study of syndromes with 
autonomic dysfunction. Our main period of interest for 
examination of risk was the year after vaccination with 
the quadrivalent human papillomavirus vaccine. This 
period was predefined and allowed for an insidious 
onset or prolonged diagnostic investigation. The two 
previous self-controlled case series analyses of bivalent 
human papillomavirus vaccination and chronic 
fatigue syndrome from the UK and the Netherlands 
also used a predefined risk period of one year after 
vaccination.13 16 Our sensitivity analyses of alternative 
risk periods found no increased rates associated with 
quadrivalent human papillomavirus vaccination.
Our study used a self-controlled case series analysis 
nested in a nationwide cohort, with independent 
ascertainment of vaccination and outcome status, thus 
reducing concerns about selection and information 
bias. Furthermore, since the self-controlled case 
series method is designed to eliminate time invariant 
confounding, lifestyle and socioeconomic factors 
are unlikely to have biased our results. A number of 
assumptions must be fulfilled for the self-controlled 
case series method to produce unbiased estimates.22 
In our study, we believe these assumptions were met, 
since the outcomes were rare, were non-fatal, and when 
we removed unvaccinated follow-up from the referent 
group in sensitivity analyses, results were consistent 
with the main analysis. We conducted sensitivity 
analyses, removing the seven days immediately before 
and after vaccination from the comparison, and 
using only vaccinated follow-up. All the results were 
consistent with the main analyses, reducing concern 
that only girls in good health are vaccinated.
Perspective
When mass vaccination is introduced in a population, 
individuals will experience adverse events in close 
temporal relation to the vaccine purely by chance.36 
In particular, chronic fatigue syndrome and postural 
orthostatic tachycardia syndrome are not uncommon 
in young adolescent girls and it is thus not surprising 
that temporal relations have been seen. Mass 
psychogenic illness has also been suggested to be a 
contributing factor to concerns about the safety of 
the human papillomavirus vaccine.37 In Colombia 
in 2014, a group of 15 girls from the same school 
presented with symptoms of autonomic dysfunction 
after human papillomavirus vaccination.38 Videos of 
these girls quickly went viral online on social media 
and more than 600 individuals with similar symptoms 
were reported from all over Colombia in the following 
weeks. The speed with which these putative links can 
spread, through television, newspapers, and social 
media, poses a challenge to public health authorities 
and regulatory agencies. In countries such as Colombia 
and Japan, uptake rates of human papillomavirus 
vaccination have dropped to such an extent that lives 
will be lost to cervical cancer as a consequence.38 39 
Hopefully, studies such as ours and innovative health 
information campaigns can turn the tide and reduce 
the damage done to human papillomavirus vaccination 
programmes worldwide.
Conclusion
In conclusion, our study does not support a 
causal association between quadrivalent human 
papillomavirus vaccination and chronic fatigue 
syndrome, complex regional pain syndrome, or 
postural orthostatic tachycardia syndrome, either 
individually or as a composite outcome. Although we 
cannot formally exclude the possibility of an increased 
risk of up to 32%, a larger increase in the rate of any 
syndrome associated with vaccination is unlikely given 
the statistical power of our study.
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